Palmieri C, Roberts-Clark D, Assadi-Sabet A, Coope R C, O'Hare M, Sunters A, Hanby A, Slade M J, Gomm J J, Lam E W-F, Coombes R C
Cancer Research UK Laboratories, Department of Cancer Medicine, MRC Cyclotron Building, Imperial College, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.
J Endocrinol. 2003 Apr;177(1):65-81. doi: 10.1677/joe.0.1770065.
Keratinocyte growth factor/fibroblast growth factor 7 (KGF/FGF7) is known to be a potent growth factor for mammary cells but its origin, cellular targets and mode of action in the breast are unclear. In this study, we carried out studies to determine the localisation of FGF7 and its receptor, and the related growth factor FGF10. We also determined the factors that regulate FGF7 release from stromal cells and the effects of FGF7 on normal and neoplastic breast cells. Using an FGF7-specific antibody which does not react with the FGF7 heparan sulphate proteoglycan (HSPG)-binding site, we showed epithelial and myoepithelial immunohistochemical staining in normal breast sections, and epithelial staining in breast carcinomas. Stromal staining was also detected in some lobular carcinomas as well as a subset of invasive ductal carcinomas. FGF10 and FGF receptor (FGFR)2 immunostaining showed a similar epithelial expression pattern, whereas no stromal staining was observed. We purified normal breast stromal, epithelial and myoepithelial cells and showed that FGF7 stimulated proliferation of both epithelial cell types, but not stromal fibroblasts. We also examined the effects of FGF7 on Matrigel-embedded organoids, containing both epithelial and myoepithelial cells, and showed FGF7 induced an increase in cellular proliferation. Furthermore, conditioned medium derived from stromal cells was shown to increase the proliferation of normal and neoplastic breast epithelial cells, which could be abolished by a neutralising antibody to FGF7. Finally, we showed that interleukin-1beta, but not oestradiol or other oestrogen receptor ligands, caused a dose-related FGF7 release. Further results also indicate that the epithelial localisation of FGF7 and FGF10 in breast tissue sections is likely to be due to their binding to their cognate receptor. In summary, our findings suggest that FGF7 is a paracrine growth factor in the breast. FGF7 is produced by the breast stromal fibroblasts and has profound proliferative and morphogenic roles on both epithelial and myoepithelial cells.
角质形成细胞生长因子/成纤维细胞生长因子7(KGF/FGF7)是一种对乳腺细胞有强大作用的生长因子,但其来源、细胞靶点及在乳腺中的作用模式尚不清楚。在本研究中,我们开展了多项研究以确定FGF7及其受体以及相关生长因子FGF10的定位。我们还确定了调节FGF7从基质细胞释放的因素以及FGF7对正常和肿瘤性乳腺细胞的影响。使用一种不与FGF7硫酸乙酰肝素蛋白聚糖(HSPG)结合位点反应的FGF7特异性抗体,我们在正常乳腺切片中显示了上皮和肌上皮免疫组化染色,在乳腺癌中显示了上皮染色。在一些小叶癌以及一部分浸润性导管癌中也检测到了基质染色。FGF10和FGF受体(FGFR)2免疫染色显示出相似的上皮表达模式,而未观察到基质染色。我们纯化了正常乳腺基质细胞、上皮细胞和肌上皮细胞,并表明FGF7刺激了两种上皮细胞类型的增殖,但不刺激基质成纤维细胞。我们还研究了FGF7对包含上皮和肌上皮细胞的基质胶包埋类器官的影响,结果显示FGF7诱导细胞增殖增加。此外,来自基质细胞的条件培养基显示可增加正常和肿瘤性乳腺上皮细胞的增殖,而这可被FGF7中和抗体消除。最后,我们表明白细胞介素-1β而非雌二醇或其他雌激素受体配体可导致与剂量相关的FGF7释放。进一步的结果还表明,FGF7和FGF10在乳腺组织切片中的上皮定位可能是由于它们与各自同源受体的结合。总之,我们的研究结果表明FGF7是乳腺中的一种旁分泌生长因子。FGF7由乳腺基质成纤维细胞产生,对上皮细胞和肌上皮细胞均具有显著的增殖和形态发生作用。